Authors: Lucy Cliff, Future Science Group
Findings published in the New England Journal of Medicine indicate the promise of zoliflodacin, a novel antibiotic that inhibits DNA synthesis, as a well-tolerated and successful treatment for uncomplicated gonorrhoea.
In the study, the team enrolled 179 participants between the ages of 18–55 with uncomplicated urogenital gonorrhea, untreated urogenital gonorrhea or sexual contact with someone with gonorrhea 14 days prior to enrolment. Participants received either 2 or 3 gram doses of oral zoliflodacin or a 500mg dose of injectable ceftriaxone.
Restricted Content / Members Only
